Clinical trials
Completed Phase 1 Astrocytoma trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
169 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 8 |
| 2001 | 9 |
| 2002 | 13 |
| 2003 | 5 |
| 2004 | 8 |
| 2005 | 11 |
| 2006 | 9 |
| 2007 | 4 |
| 2008 | 6 |
| 2009 | 12 |
| 2010 | 14 |
| 2011 | 5 |
| 2012 | 7 |
| 2013 | 5 |
| 2014 | 5 |
| 2015 | 4 |
| 2016 | 7 |
| 2017 | 3 |
| 2018 | 4 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 169 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 36 |
| Duke University | 10 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 10 |
| City of Hope Medical Center | 9 |
| Children's Oncology Group | 8 |
| Pediatric Brain Tumor Consortium | 8 |
| Jonsson Comprehensive Cancer Center | 5 |
| Memorial Sloan Kettering Cancer Center | 5 |
| National Institutes of Health Clinical Center (CC) | 5 |
| INSYS Therapeutics Inc | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Astrocytoma | 169 |
| Glioblastoma | 120 |
| Oligodendroglioma | 110 |
| Brain Neoplasms | 97 |
| Glioma | 93 |
| Gliosarcoma | 75 |
| Central Nervous System Neoplasms | 74 |
| Medulloblastoma | 53 |
| Ependymoma | 37 |
| Optic Nerve Glioma | 34 |
Trials
Showing 1 to 25 of 169. Each trial links to its page on Pharma Observatory.
69 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.